

# SHORT CURRICULUM VITAE



## 1. GENERAL

**Full Name:** Sarah Muriel Meiring  
**Work Address:** Department of Haematology and Cell Biology  
University of the Free State (UFS)  
Bloemfontein  
9300  
**Home Address:** 75 Paul Kruger Avenue  
Universitas  
Bloemfontein  
9301  
**Telephone number (W):** 051-4053593  
**Cellphone number:** 0835433367  
**Fax:** 051-4441036  
**ID Number:** 680325 0228 08 8  
**Nationality:** South African

## 2. CAREER

### 2.1 Qualifications

Matriculation Results (1986) Biology HG (B), Science HG (B), Mathematics HG (D), Afrikaans First Language HG (D), English Second Language HG (D), Accountancy SG (B).

B.Sc Degree (1987 - 1989) - Physiology 3, Biochemistry 3, Physiology 2, Biochemistry 2, Chemistry 2, Physiology 1, Zoology 1, Mathematics 2, Chemistry 1, Computer Science 1.

Honours in Physiology (1990) Physiology of Nutrition, Occupational Physiology, Electrophysiology, Physiology of Behaviourism, Physiology of the Nervous System, Hemodynamics.  
Title of project: **Die invloed van Gaboon addertoksien op die kalium- en kalsiumvloe deur ionkanale in die selmembran.**

M. Med. Sc in Haematology (1992-1994) Title of dissertation: **'n In Vitro-vloeikamer as model om die hemostatiese funksie van endoteelselle te bepaal.**

Ph. D (1994-1996) Title of thesis: **Plasma elimination of recombinant (r)-Hirudin and the r-hirudin-thrombin complex in baboons.**

Post-doctoral study (1997) Title of projects: **1) Development of monoclonal antibodies against the platelet integrin  $\alpha_2\beta_1$ -I-domain. 2) Determination of an anti-platelet Gp Ib antibody by using phage display technology. 3) Selection of antithrombotic proteins out of haematophagous parasites. 4) Expression of von Willebrand Factor mutant.**

MBA (2001-2003) Subjects: **Business Conditions Analysis, Human Resource Management, Strategy and Company Analysis, Financial and Managerial Accounting, Marketing for Managers, Behaviour in Organisations, Corporate Business Law and Ethics, Analytical Methods, E-Commerce, Project Management, Economics for Managers, Financial Management, Health Economics, Services Marketing, Strategy Dynamics and Contemporary Management Issues.**

## 2.2 Academic Awards (last 5 years):

1. In 2008, I was nominated for a National Science and Technology Forum Award in the category B: Individual through Research and Outputs over the last 5 years.
2. I received the Muller-Potgieter medal for the best laboratory article published in 2007 at our local Faculty Forum of 2008
3. A student of mine received a certificate for runner-up poster presentation at our local Faculty Forum of 2008 in the Senior laboratory category.
4. We received a certificate for runner-up poster presentation at our local Faculty Forum of 2008 in the junior laboratory category
5. In 2009, I was asked by the editorial office of the journal "European Haematology" to write an article on the "Laboratory diagnosis of Von Willebrand Disease".
6. I received the Muller-Potgieter medal for the best laboratory article published in 2009 at our local Faculty Forum of 2010
7. The NHLS saluted me for my research and service delivery work by placing an article about my work in the Business Women magazine of 2010.
8. In 2010, I received a Top 10 Award by the Department of Science and Technology for one of the best top 10 innovations in the country.
9. I received a R10 000 prize for the best poster presented at the annual congress of the South African Society for Thrombosis and haemostases
10. In 2011, an M.Med Sc student of mine received a certificate for the best oral presentation in the category Junior laboratory research at the Faculty Forum of the Faculty of Health Sciences at the University of the Free State.
11. In 2012, I receive NRF Rating in the C2 class.
12. Since 2012 I co-heads the Haemostasis Research Focus Area in the Faculty of Health Sciences at the University of the Free State.
13. In 2014 I received seed-funding of R500000 from the Technology Innovation Agency for the development of new diagnostic kits.
14. In 2016 I concluded a Service Level Agreement between the National Health Laboratory Service and the University of the Free State (UFS) for specialised haemostasis tests done in the Special Haemostasis Laboratory of the UFS.
15. In 2017, I retain my NRF rating in the C class.

## 2.3 Professional Experience (Appointments):

<i>Year</i>	<i>Appointment</i>
1990	I have done part-time work as a laboratory assistant at the Physiology Department of the Potchefstroom University.
1991 - 1996	I worked as a Medical Scientist for the University of the Free State and the Provincial Administration of the Free State.
1997	I worked as a post-doctoral student in the Laboratory for Thrombosis Research in Kortrijk, Belgium under supervision of Prof. Hans Deckmyn.
1998 – 2001	I worked as a Principle Medical Scientist for the University of the Free State and the Provincial Administration of the Free State.
2002-2009	I worked as a Specialist Scientist for the University of the Free State and the National Health Laboratory

Services.

2010-current I worked as a Specialist Scientist for the University of the Free State and the National Health Laboratory Services and I am the Research Manager of the department of Haematology and Cell Biology.

#### 2.4 Courses Attended

1. Computer courses: Lotus 1-2-3, Word 5.0 for Dos, Quattro Pro, Department of Biophysics, UFS., 1992.
2. Molecular Biology Honours course, Department of Biochemistry, UFS., 1995
3. Masters degree in Business Administration at the UFS.
4. Scientific writing, 2005, UFS
5. Sustainable Funding Strategies and Dynamic Proposal-writing Skills, UFS, April 2007
6. Project management and research, 2008
7. GCP (good clinical practice), 2009
8. Advanced project management, 2010
9. Innovation management, 2015

#### 2.5 Organizations

1. Secretary, O.F.S. Society of Medical Scientists.
2. Member, South African Haematological Society.
3. Registered at the Health Professions Council of South Africa since 1992, Registration number: MW 0007196
4. Member of the International Society for Thrombosis and Haemostasis
5. Member of the South African Society for Thrombosis and Haemostasis
6. Member of the Research and Innovation committee of the NHLS

#### 2.6 Academia

2.6.1 Reviewer: Journal of Pharmaceutical Sciences 1999-2012  
Indian Heart Journal, 2015 -2017

2.6.2 Evaluator: NRF – rating applications  
NRF – applications for research funding  
MRC – applications for research funding  
NHLSRT – applications for research funding  
NHLS – application for mentorship  
HPCSA –Internship Portfolios

2.6.3 External examiner of M.Sc and PhD degrees

2.6.4 Participation in Standardization Committee studies and discussions. I participate in the thrombin generation studies of the Standardisation Committee of the International Society on Thrombosis and Hemostasis.

2.6.5 Responsible for the setup and accreditation of the Scientist Internship Program in Haematology at the University of the Free State

2.6.5 Promotor:

1. C.R. Roets: Phage display selection of peptide inhibitors of FVIIa and their functional characterisation. **Ph.D, Faculty of Medicine, UFS, Bloemfontein, 1999- 2002.**
2. M.J. Coetzee: Selection of peptides that inhibit the pro-inflammatory stimuli, Tissue Factor. **Ph.D, Faculty of Medicine, UFS, Bloemfontein, 2004 -.**
3. N.C. Motloi: Studying factor XI activity by using phage display technology. **M.Med. Sc., Faculty of Health Sciences, UFS., Bloemfontein 2000 - 2002.**

4. K. de bruin. Construction of cDNA libraries and expression of peptides and proteins involved in thrombosis. **M.Med. Sc., Faculty of Health Sciences, UFS., Bloemfontein March 2002 - 2004**
  5. T. Abbott. Selection and expression of Tissue Factor-inhibiting antibodies from phage display libraries. **M.Med. Sc., Faculty of Health Sciences, UFS., Bloemfontein 2004 -**
  6. K. de bruin. Selection of inhibiting antibodies to ADAM-TS13. **PhD, Faculty of Health Sciences, UFS., Bloemfontein 2005 –2006**
  7. S. Mothabeng. Genetics of type 2 Von Willebrand Disease in South Africa. **M.Med. Sc., Faculty of Health Sciences, UFS., Bloemfontein 2007-2008**
  8. W. Chen. The Molecular Mechanism of Tumour-Selective Apoptosis of Curcumin in Acute Myeloid Leukemia. **PhD, Faculty of Health Sciences, UFS., Bloemfontein 2007 –2009**
  9. J. Vermeulen. Characterisation of a tissue factor inhibitory peptide. **M.Med. Sc., Faculty of Health Sciences, UFS., Bloemfontein 2008-2009**
  10. T.C. Motsoeneng. Development of an ADAMTS13 antigen assay by using phage display technology. **M.Med. Sc., Faculty of Health Sciences, UFS., Bloemfontein 2008-2009**
  11. W. Janse van Rensburg. The evaluation of Tirofiban Hydrochloride in a high shear rate arterial thrombosis model in baboons. **M.Med. Sc., Faculty of Health Sciences, UFS., Bloemfontein 2008-2009**
  12. P.Setlai. Development of an ELISA assay to measure the Von Willebrand Factor propeptide levels in human plasma. **M.Med. Sc., Faculty of Health Sciences, UFS., Bloemfontein 2011-2013.**
  13. W.E. Allers. The effect of inflammatory cytokines, tissue factor and thrombin on the synthesis of ADAMTS13 in cultures human aortic endothelial cells. **M. Med. Sc. Faculty of Health Sciences, UFS., Bloemfontein 2009 –2012**
  14. E. Le Roux. Pro-thrombotic activity of endothelial micro-particles. **M. Med. Sc. Faculty of Health Sciences, UFS., Bloemfontein 2009 –2012**
  15. M.J Coetzee. Setting up of a bleeding disorder register in the Northern Cape and Free State. **PhD, Faculty of Health Sciences, UFS., Bloemfontein 2010 – 2014**
  16. L. Cloete. Development of a factor VIII binding assay using phage display technology. **M. Med. Sc. Faculty of Health Sciences, UFS., Bloemfontein 2011 –2013**
  17. M Khemisi. Thrombogenicity of tissue engineered blood vessels. **M.Med. Sc, Faculty of Health Sciences, UFS., Bloemfontein 2013 – 2014**
  18. **J. Vermeulen.** Optimised large-scale production and *in vitro* characterisation of an anti-tissue factor scFv. **PhD, Faculty of Health Sciences, UFS. Bloemfontein 2013 – 2017**
  19. R. Maleka. Validation of a Von Willebrand factor-propeptide assay. **M. Med. Sc. Faculty of Health Sciences, UFS., Bloemfontein 2015 –2016**
  20. M. Khemisi. Characterisation of ADAMTS epitopes of auto-antibodies in patients with HIV-associated TTP. **PhD, Faculty of Health Sciences, UFS., Bloemfontein 2016 – 2018**
  21. C. Blaauw. Seeding of vascular grafts with endothelial progenitor cells. **M.Sc Faculty of Health Sciences, UFS., Bloemfontein 2017-2019**
- 2.6.6 Training of HPCSA Medical Intern Scientists:
1. Lindie Cloete 2012-2014
  2. Precious Setlai 2013-2015
  3. Mmakgabu Khemisi 2014-2016
  4. Sne Myeni 2016
  5. Rethabile Maleka 2017 - 2018

## 2.7 Bursaries and funds

1. I received R20 000 per year from the MRC (1999-2001) and R50 000 per year for 2005 and 2006.
2. I received R10 000 per year from the Central Research Fund of the University of the Free State (1998-2001)
3. I received R80 000 per year from the National Research Foundation for a project in collaboration with the laboratory of Prof. Jolan Harsfalvi from Debrecen, Hungary. The duration of the project "New antithrombotics: role in platelet adhesion and coagulation" using Phage Display libraries, Combinatorial Chemistry, *in vitro* Primary Haemostasis Model and Animal models is 3 years (2000-2002) with renewal to 2005. This collaboration is renewed for 2 years to 2007 with an amount of R200 000
4. I received R70 000 per year for 2 years from the National Research Foundation for a project in collaboration with the laboratory of Prof. Hans Deckmyn from Kortrijk, Belgium with title "New antithrombotics: role in platelet aggregation, coagulation and restenosis" (2002-2003). The research project contains three work packages:
  - a) Antistenotic effect of platelet adhesion inhibitors (KULAK, SA UIA).
  - b) Atherosclerosis (UIA, SA)
  - c) Differential inhibition of the action of thrombin (SA, KULAK)This agreement is renewed to 2006 with an amount of R70 000 per year.
5. I am in charge of a collaboration with Dr Marc Jacquemin from the Center for Molecular and Vascular Biology, University of Leuven, Belgium where we received R65 000 per year from the National Research Foundation. Title of project: Preclinical evaluation in non-human primates of a novel type of antithrombotic agent: anti-factor VIII monoclonal antibodies.
6. I received R50 000 per year for 2005 and 2006 from the NHLS Research Trust for the project "Construction and functional testing of recombinant carboxyl-terminal CUB domains of ADAMTS-13"
7. In 2007 I received a THUTUKA grand for Women in Research from the National Research Foundation for a period of 6 years (R200 000 per year).
8. I received a research grand from the medical Research Council of R50 000 per year for 2 years for the project "The Molecular Mechanism of Tumour-Selective Apoptosis of Curcumin in Acute Myeloid Leukemia".
9. I receive the NHLS Research Trust Pathology Award of R500 000 in 2011 for 3 years for the project "Haemostatic Disorders: Cost effective improvement in Laboratory Diagnosis and Treatment"
10. In 2014, I received an Interdisciplinary Collaboration Grant from the University of the Free State of R100 000 for "The development of novel assay kits for haemostatic disorders".
11. I received a Seed Fund Grant from the Technology and Innovation Agency (TIA) of R500 000 in 2015 for the project "Development of a Von Willebrand factor Propeptide assay kit".
12. I received a research grand from the NRF of R200 000 per year for 3 years (2015-2017) in the program: Competitive grants for rated researchers for the project "HIV- Associated TTP – Identification of ADAMTS13 auto-antibody epitopes".
13. I received the NHLS pathology Award of R500 000 in 2018-2020 for the project "Micro-particles in thrombosis and Haemostasis"

## 2.8 Contract with the Pharmaceutical Company, American Diagnostica (ADI)

I concluded a collaboration agreement with ADI from 2000 to 2003. The contract consists of the following. We receive reagents worth more than R400 000 per year from them for projects to develop novel antithrombotics. We also receive an amount of US\$7000 per quarter for reagents, manpower and consumables. The company synthesized the peptides which we selected, and we test it in our animal models. The patent costs are carried by the company and we receive a percentage (10%) of the patent rights for these products.

## 2.9 *Contract with other Pharmaceutical Companies,*

### *ABLYNX (Belgium)*

I concluded a collaboration agreement with ABLYNX in 2004. The company synthesized antibodies that inhibit thrombosis. We test these antibodies for their antithrombotic effect in primates.

### *ThrombX (Belgium)*

I am also in charge of the collaboration agreement with Thromb-X which we concluded in 2002. We also test antibodies for antithrombotic effect in primates.

### *Kanacia (Australia)*

I concluded a collaboration agreement with Kanacia in 2005. The company synthesized natural drugs that inhibit thrombosis. We test these drugs for their antiplatelet effect in primates.

### *Pierre Fabre (France)*

I concluded a collaboration agreement with Pierre Fabre in 2006. The company also synthesized natural drugs that inhibit thrombosis. We test these drugs for their antiplatelet effect in primates.

### *Sanofi- Aventis (Germany)*

I conclude a collaboration agreement with Sanofi-Aventis in 2009. We also test their anti-thrombotic drugs in our primate thrombosis model.

### *Central University of Technology (CUT)*

Since 2011 I perform contract research for the CUT.

### *National Bioproducts Institute (NBI)*

We test products of the NBI for their quality control purposes since 2009.

### *Van Rensburg Pathologists (VRP)*

We perform specialised haemostasis tests for VRP as part of several research projects.

### *Kabi Diagnostics*

We prepare and perform interleukin measurements on blood samples of patients participating in a fish-oil study.

### *North West University (NWU)*

Since 2011 I perform contract research for the NWU.

### *NHLS and UFS Service Level agreement*

Since 2016 a service level agreement was formed between the NHLS and UFS in order to provide special haemostasis tests to the state and private sector.

## 2.10 *Laboratory Services*

### **Specialised Haemostasis Laboratory**

I manage the Specialised Haemostasis Laboratory of the University of the Free State and the NHLS. In 2003, I developed our Von Willebrand's disease testing facility and established our laboratory not only to become a reference centre for Von Willebrand's disease in South Africa, but also as a centre of excellence for Von Willebrand's disease, the most common bleeding disorder in the world. We are the only laboratory in South Africa that performs all the diagnostic tests needed for the accurate diagnosis of Von Willebrand's disease. We perform these tests as a service to a variety of laboratories across the country. We enjoy international recognition as a VWD centre of excellence and perform the multimeric analysis of VWF for the external quality assurance program of the Royal College of Pathologists of Australia (RCPA). The extensive scope of tests for the Specialised Haemostasis laboratory includes the following: VWF antigen, VWF ristocetin cofactor, VWF collagen binding assay, VWF multimeric analysis, VWF-factor VIII binding assay, thrombo-estastography, platelet sensitivity studies, platelet aggregometry, platelet impedance assay, ADAMTS13 antigen assay, ADAMTS13 activity assay, ADAMTS13 auto-antibody assay, Interleukin-6- and TNF-alpha levels, thrombin generation assay and the microparticle thrombin generation assay.

## 2.11 Collaborations

### Current Collaborations

With Prof Hans Deckmyn from the Laboratory for Thrombosis Research at the University of Leuven, Campus Kortrijk. Prof Deckmyn's laboratory develops antithrombotics that block the binding of platelets to VWF. These antithrombotic drugs are tested in our laboratory for efficacy in our baboon model for arterial thrombosis. The funding of this collaboration has stopped at the end of 2007 by the Flemish Government. No new collaborations between the two governments are established since then.

With Prof Jolan Harsfalvi from the Department of Haematology, University of Debrecen, Hungary. Both laboratories select peptides and antibodies that inhibit blood coagulation and platelet adhesion. These peptides and antibodies are currently further characterized *in vitro* using thrombin generation assay, different perfusion chambers and *in vivo* in primates. The group in Debrecen is experienced in using biochemical-, immuno assays and different perfusion chambers (parallel plate, cone and plate) for studying platelet adhesion under well-defined shear conditions. The group in Bloemfontein on the other hand has ample experience with baboon thrombosis models. Inhibitors of both platelet aggregation and of coagulation will be analysed for their antithrombotic effects in baboon models.

With Dr Emmanuel Favaloro from the department of Haematology and the RCPA external quality assurance program, Institute for Clinical Pathology and Medical Research, Westmead Hospital, New South Wales, Australia. Our laboratory perform multimeric analysis of the blood samples that are sent out by the RCPA quality assurance program. We also further investigate interesting VWD cases such as rare collagen binding defects together.

## 3. LIST OF PUBLICATIONS

1. Kotzé H.F., Badenhorst P.N., Lamprecht S., Meiring S.M., Van Wyk C, Nuyts K., Stassen J.M., Vermylen J., Deckmyn H. (1995). Prolonged inhibition of acute arterial thrombosis by high dosing of a monoclonal anti-platelet glycoprotein IIb/IIIa antibody in a baboon model. *Thrombosis and Haemostasis* **74**: 751-757.
2. Meiring S.M., Kotzé H.F., Pretorius G.H.J., Badenhorst P.N. (1995). 'n *In vitro* - vloekamer as model om die hemostatiese funksie van lewende *in situ* - endoteelselle te bepaal. *Die Suid-Afrikaanse Tydskrif vir Wetenskap en Tegnologie*, **14(4)**: 102 - 110.
3. Meiring S.M., Lötter M.G., Badenhorst P.N., Bucha E., Nowak G., Kotzé H.F. (1999). Sites of elimination and pharmacokinetics of recombinant <sup>131</sup>I-lepirudin in baboons. *Journal of Pharmaceutical Sciences*, **88(5)**: 523-529.
4. Meiring SM, Kotzé HF, Pretorius GHJ, Badenhorst PN. (1999). Die toepassing van peptiedblootlegging op fage in trombose en hemostase (The application of phage display technology in thrombosis and haemostasis). *Suid-Afrikaanse Tydskrif vir Natuurwetenskap en Tegnologie (South African Journal of Science and Technology)* **18**:76-81.
5. Cauwenberghs N, Meiring M, Vautarin S, Van Wyk V, Lamprecht S, Roodt JP, Novak L, Harsfalvi J, Deckmyn H. Kotzé HF. (2000). Antithrombotic effect of platelet glycoprotein Ib blocking monoclonal antibody Fab fragments in non-human primates. *Arteriosclerosis, Thrombosis and Vascular Biology* **20**:1347-1353.
6. Viaene A., Crab A., Meiring M., Pritchard D., Deckmyn H. June (2001). Identification of a collagen-binding protein from *Necator americanus* by using a cDNA-expression phage library. *Journal of Parasitology* **87(3)**: 619-625.
7. S.M. Meiring, J. Harsfalvi, V. van Wyk, P.N. Badenhorst, H.F. Kotzé (2002). In vitro effect of a novel thrombin inhibition peptide, TIP, selected by phage display technology. *Thrombosis Research* **107**: 365-371.
8. Wu D, Meiring SM, Kotzé HF, Deckmyn H, Cauwenberghs N (2002). Inhibition of platelet glycoprotein Ib, Glycoprotein IIb/IIIa, or both by monoclonal antibodies prevents arterial thrombosis in baboons. *Arteriosclerosis Thrombosis and Vascular Biology* **22**: 323-328.

9. Wu D, Vanhoorelbeke K, Cauwenberghs N, Meiring SM, Depraetere H, Kotzé HF, Deckmyn H (2002). Inhibition of the von Willebrand-collagen interaction by an antihuman VWF monoclonal antibody results in abolition of *in vivo* arterial platelet thrombus formation in baboons. *Blood* **99**:3623-3628.
10. Meiring SM, Badenhorst PN, Kelderman M (2005). The use of an algorithm for the Laboratory Diagnosis of Von Willebrand Disease. *Medical Technology SA* **19**: 15-18.
11. Meiring SM, Badenhorst PN, Kelderman M (2005). The use of an algorithm for the laboratory diagnosis of von Willebrand disease. *Medical Technology SA* **19(1)**: 15-18.
12. Meiring SM, Badenhorst PN, Kelderman M (2005). A rapid and cost-effective method to visualise von Willebrand Factor multimeres in plasma. *Medical Technology SA* **19(2)**: 15-20.
13. Meiring SM, Roets CE, Badenhorst PN (2006). Funksionele beskrywing van 'n faktor VIIa-inhiberende peptied, IP-7, geselekteer deur faagblootleggingstechnologie. *Die Suid Afrikaanse Tydskrif vir Wetenskap en Tegnologie*. **25(4)**:209-220.
14. Mansvelt E, Jongh G, Wessels G, Fourie E, Meiring SM, Tuddenham E. Haemophilia A in a female patient: 04 PO 67 (2006). *Haemophilia*. **12 Suppl. 2:10**.
15. Meiring SM, Badenhorst PN, Kelderman M (2007). Performance and utility of a cost-effective collagen binding assay for the laboratory diagnosis of Von Willebrand disease. *Clinical Chemistry and Laboratory Medicine*. **45(8)**: 1068-1072.
16. Favalaro EJ, Bonar R, Meiring SM, Street A, Marsden K (2007). 2B or not 2B? Disparate discrimination of functional VWF discordance using different assay panes or methodologies may lead to success or failure in the early identification of Type 2B VWD. *Thrombosis and Haemostasis* **98**: 346 – 358.
17. Simon F de Meyer, Stephanie Staelens, Philip N Badenhorst, Henry Pieters, Seb Lamprecht, Jan Roodt, Stefan Janssens, Muriel Meiring, Karen Vanhoorelbeke, André Bruwer, Stephen Brown, Hans Deckmyn. Coronary artery in-stent stenosis persists despite inhibition of the von Willebrand factor – collagen interaction in baboons. *Thrombosis and Haemostasis* 2007; **98**: 1343-1349.
18. Coetzee M, Mothabeng S, Meiring M, Nel M, Brussow M (2008). The prevalence of risk factors for thrombosis in a random sample of haemophilia A patients in Central South Africa 14 . *Haemophilia*
19. Meiring SM, Vermeulen J, Badenhorst PN (2009). Development and Functional Characterisation of an Inhibitory Antibody Fragment to Human Tissue Factor. *Drug Development Research* **70**:199-205.
20. Favalaro EJ, Thom J, Patterson D, Just S, Baccala M, Dixon T, Meiring SM, Koutts J, Rowell J, Baker R (2009). Potential supplementary utility of combined PFA-100 a functional VWF testing for the laboratory assessment of desmopressin and factor concentrate therapy in von Willebrand disease. *Blood Coagulation and Fibrinolysis* **20(6)**: 475-483.
21. Meiring SM, Kelderman M, Badenhorst PN (2009). Laboratory diagnosis of Von Willebrand Disease. *European Haematology* **3(1)**: 33-36.
22. Feys HB, Roodt J, Vandeputte N, Pareyn I, Lamprecht S, Janse Van Rensburg W, Anderson PJ, Budde U, Louw VJ, Meiring M, Deckmyn H, Vanhoorelbeke K (2010). Thrombotic thrombocytopenic purpura directly linked with ADAMTS13 inhibition in the baboon (*Papio ursinus*). *Submitted to Blood*.
23. Jafta AD, Meiring SM, Conradie C (2010). Valproic Acid associated platelet dysfunction: Case Report. *African journal of Haematology and Oncology* **1(2)**: 15.
24. Chen W, Leiter A, Dong Y, Meiring M, Louw V, Koeffler P (2010). Cucurbitan B inhibits growth, arrests the cell cycle and potentiates antiproliferative efficacy of cisplatin in cutaneous squamous cell carcinoma cell lines. *International Journal of Oncology* **37(3)**: 737-743.
25. Meiring SM, Kelderman M, Coetzee MJ, Badenhorst PN (2011). Laboratory Diagnosis and management of von Willebrand Disease in South Africa. *Seminars in Thrombosis and Haemostasis* **37(5)**: 576.



26. Meiring SM, Webb M, Goedhals D, Louw V (2012). HIV associated Thrombotic Thrombocytopenic Purpura – What we know so far. *European Oncology and Haematology*, **8(2)**:89-91.
27. Favalaro EJ, Bonar R, Chapman K, Meiring M, Funk D (2012). Differential sensitivity of Von Willebrand factor (VWF) “activity” assays to large and small molecular weight forms: a cross-laboratory study comparing ristocetin cofactor, collagen-binding and mAb-based assays. *Journal of Thrombosis and Haemostasis* **10(6)**: 1043-1054.
28. Malan N, Von Kanel R, Schutte A, Huisman H, Smith W, Mels C, Kruger K, Meiring M, Van Rooyen J, Malan L (2013). Testosterone and acute stress are associated with fibrinogen and von Willebrand factor in African men: The SABPA study. *International Journal of Cardiology* **168(5)**: 4638-4642.
29. Von Kanel R, Hamer M, Malan N, Scheepers K, Meiring M, Malan L (2013). Procoagulant reactivity to laboratory acute mental stress in Africans and Caucasians and its relation to depressive symptom: The SABPA Study. *Thrombosis and Haemostasis* **110(5)**: 977 -986.
30. Favalaro EJ, Bonar R, Meiring M, Duncan E, Mohammed S, Sioufi J, Marsden K (2014). Evaluating errors in the laboratory identification of von Willebrand disease in the real world *Thrombosis Research* **90(4)**: 393-403.
31. Allie S, Stanley A, Bryer A, Meiring M, Combrinck MI (2015). High levels of von Willebrand factor and low levels of its cleaving protease, ADAMTS13, are associated with stroke in young HIV-infected patients. *International Journal of Stroke* **10(8)**:1294-1296.
32. Meiring M, Allers W, Le Roux E (2016). Tissue Factor: a potent stimulator of Von Willebrand factor synthesis by human umbilical vein endothelial cells. *International Journal of Medical Science* **13(10)**: 759-764.
33. Favalaro EJ, Bonar RA, Mohammed S, Arbelaez A, Niemann J, Freney R, Meiring M, Sioufi J, Marsden, K. Type 2M von Willebrand disease – more often misidentified than correctly identified. *Haemophilia* 2016;22:e145-e55. DOI: 10.1111/hae.12903.
34. Meiring M, Myneni S (2017). Evaluation of a cost-effective ADAMTS13 antigen assay. *Medical Technology SA* **31(1)**: 1-4.
35. Meiring M, Khemisi M, Laker L, Dohmen PM, Smit FE (2017). Tissue engineered small vessel conduits – the anti-thrombotic effect of re-endothelialisation of decellularized baboon arteries: a preliminary experimental study. *Medical Science Monitor Basic Research* **23**: 344-251.

#### 4. PATENT APPLICATIONS

1. Inhibitory antibody fragments to human Tissue Factor. Meiring SM, 2009.
2. ADAMTS13 antigen kit. Meiring SM, 2010
3. Von Willebrand Factor propeptide antigen kit. Meiring SM 2014

#### 5. CONGRESS PRESENTATIONS

International = 36  
 National = 54  
 Local = 63

#### 6. REFEREES

- |  |   |
|--|---|
| <ol style="list-style-type: none"> <li>1. Prof. M.J.Coetzee<br/>           Department of Haematology,<br/>           University of the Free State<br/>           BLOEMFONTEIN<br/>           9300<br/>           Tel: (051) 4053043</li> </ol> | <ol style="list-style-type: none"> <li>2. Prof. Harry Kotzé<br/>           Research Administration<br/>           University of the Free State<br/>           BLOEMFONTEIN<br/>           9300<br/>           Tel: (051) 4013749</li> </ol> |
|--|---|

